val cit pab mmae

Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE . MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization[1].

Amino-PEG4-Val-Cit-PAB-MMAE is a cleavable tetraethylene glycol (4 unit PEG) antibody-drug conjugate (ADC) linker used in the synthesis of ADCs[1].

Endo-BCN-PEG4-Val-Cit-PAB-MMAE is a cleavable four-unit polyethylene glycol (PEG) linker, specifically designed for the synthesis of antibody-drug conjugates (ADCs)[1].

Fmoc-Val-Cit-PAB-MMAE is consisted of the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Fmoc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC.

MAL-di-EG-Val-Cit-PAB-MMAE consists of the linker MAL-di-EG-Val-Cit-PAB and the potent tubulin inhibitor MMAE, both of which are crucial components of antibody-drug conjugates (ADCs).

Mal-PEG8-Val-Cit-PAB-MMAE is a cleavable 8-unit PEG ADC linker utilized in the synthesis of antibody-drug conjugates (ADCs)[1].

SuO-Val-Cit-PAB-MMAE is an ADC (antibody-drug conjugate) linker composed of the anti-mitotic monomethyl auristatin E (MMAE, a tubulin inhibitor) linked via the SuO-Val-Cit-PAB peptide.

Mal-PEG4-Val-Cit-PAB-MMAE is the linker-payload component of an antibody-conjugated active molecule (ADC), consisting of a degradable ADC linker and the microtubule inhibitor MMAE.

DBCO-Val-Cit-PAB-MMAE is a drug-linker conjugate employed in the synthesis of ADC (antibody-drug conjugate) molecules. MMAE acts as a microtubule inhibitor, serving as the cytotoxic agent in ADCs. DBCO-Val-Cit-PAB functions as a linker with electrophilic groups.

Azido-PEG4-Val-Cit-PAB-MMAE is a drug-linker conjugate for antibody-drug conjugates (ADCs), incorporating the tubulin inhibitor monomethyl auristatin E (MMAE) and linked via the cleavable Azido-PEG4-Val-Cit-PAB-OH.

SuO-Glu-Val-Cit-PAB-MMAE is a chemical compound consisting of a cleavable ADC linker (SuO-Glu-Val-Cit-PAB) and a potent tubulin inhibitor (MMAE). It is employed in the synthesis of antibody-drug conjugates (ADCs).

mDPR-Val-Cit-PAB-MMAE consists the ADCs linker (mDPR-Val-Cit-PAB) and potent tubulin inhibitor (MMAE), mDPR-Val-Cit-PAB-MMAE is an antibody drug conjugate.

OH-Glu-Val-Cit-PAB-MMAE is a compound consisting of a cleavable ADC linker (OH-Glu-Val-Cit-PAB) and a potent tubulin inhibitor (MMAE), used in the synthesis of antibody-drug conjugates (ADCs) [1].

(Aminooxy)acetamide-Val-Cit-PAB-MMAE (MMAE 5) serves as an intermediate for synthesizing drug-linker conjugates in antibody-drug conjugates (ADCs). The compound is initially conjugated to a polyamide via oxime bond formation, forming an MMAE polyamide conjugate, which is then attached to Trastuzumab to create the ADC [1].

PSMA-Val-Cit-PAB-MMAE is a novel PSMA-targeted small-molecule conjugate utilizing monomethyl auristatin E (MMAE) for prostate cancer chemotherapy.

mDPR-Val-Cit-PAB-MMAE TFA is a drug-linker conjugate for antibody-drug conjugates (ADC), comprising the tubulin polymerization inhibitor MMAE coupled with an ADC-specific peptide linker (Val-Cit-PAB) [1].

DBCO-PEG2-Val-Cit-PAB-MMAE is an ADC linker featuring a DBCO group, a Val-Cit dipeptide, a PAB moiety, and an MMAE payload. The DBCO group serves as a click chemistry handle that can react with azide groups, while the Val-Cit dipeptide is protease-cleavable, enabling the release of the MMAE payload into cells through an elimination mechanism.

Mc-Val-Cit-PAB-Cl, a cleavable ADC linker, is utilized in the conjugation of MMAE and antibodies to produce compounds such as antibody-MC-vc-MMAE (e.g., anti-CD22-MC-VC-PABC-MMAE), which demonstrate cytotoxicity with IC50s of 3.3 and 0.95 nM against BJAB and WSU cell lines, respectively.

Mal-PEG8-Val-Cit-PAB-MMAF, a drug-linker conjugate utilized for antibody-drug conjugates (ADCs), includes a cleavable linker system and the potent tubulin inhibitor monomethyl auristatin F (MMAF), designed for targeted cancer therapy.

Val-Cit-PAB-MMAE is a molecular entity designed to function as an antibody-drug conjugate (ADC) or as a component of bispecific antigen-binding molecules, specifically targeting the hepatocyte growth factor receptor known as c-Met (MET).